ARS Pharmaceuticals
SPRY
100 hedge funds and large institutions have $359M invested in ARS Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 30 increasing their positions, 29 reducing their positions, and 16 closing their positions.
70% more call options, than puts
Call options by funds: $3.99M | Put options by funds: $2.35M
43% more capital invested
Capital invested by funds: $252M → $359M (+$108M)
19% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 16
3% more funds holding
Funds holding: 97 → 100 (+3)
3% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 29
1.36% less ownership
Funds ownership: 69.62% → 68.26% (-1.4%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$2.2M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$2.18M |
| 3 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$1.36M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$1.01M |
| 5 |
Morgan Stanley
New York
|
+$577K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$4.15M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$3.04M |
| 3 |
CST
Charles Schwab Trust
Henderson,
Nevada
|
-$1.1M |
| 4 |
CC
Clearline Capital
New York
|
-$1.03M |
| 5 |
Vontobel Holding
Zurich,
Switzerland
|
-$985K |
SPRY Hedge Fund Activity: Q4 2023 in Review
100 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in ARS Pharmaceuticals (SPRY) for Q4 2023, worth a combined $359M — up 43% from $252M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new SPRY positions and 16 closed out — a net gain of 3 holders — while 30 added to existing stakes and 29 trimmed.
The largest buyer was K2 Principal Fund, adding an estimated $2.2M. The largest seller was Millennium Management, exiting entirely with an estimated $4.15M sold.
- 100 institutional investors held ARS Pharmaceuticals (SPRY) as of Q4 2023, up from 97 in Q3 2023.
- Funds reported $359M of ARS Pharmaceuticals stock for Q4 2023, up 43% quarter-over-quarter.
- 19 funds opened new ARS Pharmaceuticals positions in Q4 2023 and 16 closed out, a net change of +3 holders.
- The largest ARS Pharmaceuticals buyer in Q4 2023 was K2 Principal Fund, an estimated $2.2M added.
- The largest ARS Pharmaceuticals seller in Q4 2023 was Millennium Management, an estimated $4.15M sold.
Based on aggregated 13F filings for Q4 2023.